Neuroinflammation in Aged Brain: Impact of the Oral Administration of Ellagic Acid Microdispersion.
Administration, Oral
Aging
/ drug effects
Animals
Anti-Inflammatory Agents
/ administration & dosage
Brain
/ drug effects
Calcium-Binding Proteins
/ genetics
Ellagic Acid
/ administration & dosage
Glial Fibrillary Acidic Protein
/ genetics
Interleukin-1beta
/ genetics
Leukocyte Common Antigens
/ genetics
Male
Memory
Mice
Mice, Inbred C57BL
Microfilament Proteins
/ genetics
Movement
CD45
EA microdispersion (EAm)
GFAP
aging
behavioral skills
ellagic acid (EA)
mice
noradrenaline
oral administration
principal component analysis (PCA)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
25
04
2020
revised:
13
05
2020
accepted:
19
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
17
2
2021
Statut:
epublish
Résumé
The immune system and the central nervous system message each other to preserving central homeostasis. Both systems undergo changes during aging that determine central age-related defects. Ellagic acid (EA) is a natural product which is beneficial in both peripheral and central diseases, including aging. We analyzed the impact of the oral administration of a new oral ellagic acid micro-dispersion (EAm), that largely increased the EA solubility, in young and old mice. Oral EAm did not modify animal weight and behavioral skills in young and old mice, but significantly recovered changes in "ex-vivo, in vitro" parameters in old animals. Cortical noradrenaline exocytosis decreased in aged mice. EAm administration did not modify noradrenaline overflow in young animals, but recovered it in old mice. Furthermore, GFAP staining was increased in the cortex of aged mice, while IBA-1 and CD45 immunopositivities were unchanged when compared to young ones. EAm treatment significantly reduced CD45 signal in both young and old cortical lysates; it diminished GFAP immunopositivity in young mice, but failed to affect IBA-1 expression in both young and old animals. Finally, EAm treatment significantly reduced IL1beta expression in old mice. These results suggest that EAm is beneficial to aging and represents a nutraceutical ingredient for elders.
Identifiants
pubmed: 32455600
pii: ijms21103631
doi: 10.3390/ijms21103631
pmc: PMC7279224
pii:
doi:
Substances chimiques
Aif1 protein, mouse
0
Anti-Inflammatory Agents
0
Calcium-Binding Proteins
0
Glial Fibrillary Acidic Protein
0
Interleukin-1beta
0
Microfilament Proteins
0
Ellagic Acid
19YRN3ZS9P
Leukocyte Common Antigens
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Interreg
ID : ALCOTRA 1198 (2017-2020)
Références
Daru. 2019 Dec;27(2):721-733
pubmed: 31736017
Neuropharmacology. 2019 Feb;145(Pt A):75-86
pubmed: 29402503
Pharm Biol. 2017 Dec;55(1):1679-1687
pubmed: 28447514
Evid Based Complement Alternat Med. 2013;2013:932401
pubmed: 24159353
J Pharm Biomed Anal. 2006 Jan 23;40(1):206-10
pubmed: 16111850
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Sep;1863(9):958-967
pubmed: 29793057
J Neurochem. 2012 May;121(3):428-37
pubmed: 22385043
J Neural Transm (Vienna). 2009 Aug;116(8):1007-16
pubmed: 19343473
Nutrients. 2017 Aug 30;9(9):
pubmed: 28867799
Eur J Pharmacol. 2012 May 5;682(1-3):118-25
pubmed: 22387858
Pharmacol Rep. 2012;64(4):796-807
pubmed: 23087132
Neuropharmacology. 2017 May 1;117:21-32
pubmed: 28132781
Am J Clin Nutr. 2020 Jan 1;111(1):170-177
pubmed: 31711104
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Dec 20;95:109703
pubmed: 31325470
Gerontology. 2013;59(1):23-31
pubmed: 22947921
Neurochem Int. 2008 Jan;52(1-2):52-9
pubmed: 17640770
Neurobiol Dis. 2013 Jul;55:110-9
pubmed: 23454193
Food Funct. 2019 Sep 1;10(9):6135-6146
pubmed: 31497826
Evid Based Complement Alternat Med. 2013;2013:946298
pubmed: 23970941
Brain Struct Funct. 2015;220(3):1681-93
pubmed: 24659256
Neurochem Int. 2004 Sep;45(4):443-51
pubmed: 15186910
Front Immunol. 2017 Sep 04;8:1079
pubmed: 28928746
Neurobiol Aging. 2014 Jan;35(1):15-23
pubmed: 23969179
PLoS One. 2017 Jan 26;12(1):e0170825
pubmed: 28125677
Neuropeptides. 2019 Aug;76:101928
pubmed: 31078318
BMC Complement Altern Med. 2017 Jan 14;17(1):47
pubmed: 28088220
Int J Mol Sci. 2019 Jul 25;20(15):
pubmed: 31349638
Brain Res. 2017 May 1;1662:23-30
pubmed: 28238669
Curr Med Chem. 2019;26(20):3670-3684
pubmed: 29493441
Front Aging Neurosci. 2019 Mar 19;11:59
pubmed: 30941031
Psychoneuroendocrinology. 2015 Dec;62:36-46
pubmed: 26231445
Front Pharmacol. 2016 Aug 31;7:295
pubmed: 27630571
Neuropharmacology. 2007 Jul;53(1):27-36
pubmed: 17543354
Carbohydr Polym. 2015 Oct 20;131:306-14
pubmed: 26256189
J Gerontol A Biol Sci Med Sci. 2014 Nov;69(11):1325-30
pubmed: 24809352
Front Aging Neurosci. 2016 Jul 06;8:161
pubmed: 27458371
Eur J Med Chem. 2019 Dec 1;183:111724
pubmed: 31563012
Trends Cogn Sci. 2016 Mar;20(3):214-226
pubmed: 26895736
Curr Pharm Des. 2019;25(39):4168-4174
pubmed: 31721696
Life Sci. 2015 Mar 1;124:120-7
pubmed: 25637685
PLoS One. 2017 Dec 19;12(12):e0189821
pubmed: 29261743
Curr Pharm Des. 2016;22(10):1350-60
pubmed: 26806345
J Agric Food Chem. 2014 Jul 16;62(28):6535-8
pubmed: 24976365
Neuropathol Appl Neurobiol. 2017 Jun;43(4):281-298
pubmed: 27442752
J Immunol. 2016 Apr 15;196(8):3318-30
pubmed: 26962232
Int J Mol Sci. 2018 Mar 01;19(3):
pubmed: 29494550
Int J Med Sci. 2019 Oct 5;16(11):1473-1479
pubmed: 31673239
Neuropharmacology. 2016 Aug;107:131-145
pubmed: 26965219